deCODE Submits IND on DG051 for the Prevention of Heart Attack
June 29 2006 - 5:01PM
PR Newswire (US)
REYKJAVIK, Iceland, June 29 /PRNewswire-FirstCall/ -- deCODE
genetics (NASDAQ:DCGN) today announced that it has submitted an
investigational new drug application (IND) to the US Food and Drug
Administration (FDA) for DG051, the company's follow-on
investigational compound for the prevention of heart attack.
Pending clearance by the FDA, the company expects to begin Phase I
clinical testing of the compound later this summer. "Through our
gene discovery work we have developed a new understanding of the
role of the leukotriene pathway in modulating the risk of heart
attack. We now have two compounds in clinical development designed
to control this pathway, programs which are landmarks in the
advancement of novel means to combat the leading cause of death in
the industrialized world. With DG031 in Phase III, bringing forward
DG051 is an important component of deCODE's strategy to deliver on
the therapeutic and commercial potential of targeting this pathway,
leveraging our solid intellectual property position both swiftly
and well into the future," said Kari Stefansson, CEO of deCODE.
DG051 is a novel small-molecule inhibitor of leukotriene A4
hydrolase (LTA4H), the protein made by one of the genes in the
leukotriene pathway deCODE has linked to risk of heart attack. Like
DG031, the company's lead compound for the prevention of heart
attack now in a Phase III clinical trial, DG051 is designed to
decrease risk of heart attack by decreasing the production of
leukotriene B4 (LTB4), an end product of the leukotriene pathway
and a potent promoter of inflammation. DG051 was discovered by
deCODE's structural biology and chemistry groups, and in
preclinical studies it has been shown in human blood ex vivo and in
animal models to be a potent inhibitor of LTB4 production. About
deCODE deCODE genetics (NASDAQ:DCGN) is a global leader in applying
human genetics to develop drugs for common diseases. Our population
approach has enabled us to discover and target key biological
pathways involved in conditions ranging from heart attack to
cancer. We are turning these discoveries into new medicine to
better treat and prevent many of the biggest challenges to public
health. deCODE is delivering on the promise of the new
genetics(SM). Visit us on the web at http://www.decode.com/. Any
statements contained in this presentation that relate to future
plans, events or performance are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements are subject to a number of
risks and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
These risks and uncertainties include, among others, those relating
to technology and product development, integration of acquired
businesses, market acceptance, government regulation and regulatory
approval processes, intellectual property rights and litigation,
dependence on collaborative relationships, ability to obtain
financing, competitive products, industry trends and other risks
identified in deCODE's filings with the Securities and Exchange
Commission. deCODE undertakes no obligation to update or alter
these forward-looking statements as a result of new information,
future events or otherwise. Contact: deCODE genetics Edward Farmer
Joy Bessenger +1 212 343 2819 +1 212 481 3891 DATASOURCE: deCODE
genetics CONTACT: Edward Farmer, +1-212-343-2819, , or Joy
Bessenger, +1-212-481-3891, , both of deCODE genetics Web site:
http://www.decode.com/
Copyright
Decode Genetics (MM) (NASDAQ:DCGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Decode Genetics (MM) (NASDAQ:DCGN)
Historical Stock Chart
From Jul 2023 to Jul 2024